Entera Bio Ltd
NASDAQ:ENTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.5507
2.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Entera Bio Ltd
Entera Bio Ltd
Cost of Revenue
Entera Bio Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cost of Revenue
-$90k
|
CAGR 3-Years
33%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cost of Revenue
-$1.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cost of Revenue
-$91m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cost of Revenue
-$8.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cost of Revenue
-$130k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-130%
|
CAGR 10-Years
-28%
|
|
Entera Bio Ltd
Glance View
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.
See Also
What is Entera Bio Ltd's Cost of Revenue?
Cost of Revenue
-90k
USD
Based on the financial report for Sep 30, 2024, Entera Bio Ltd's Cost of Revenue amounts to -90k USD.
What is Entera Bio Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
2%
Over the last year, the Cost of Revenue growth was -800%. The average annual Cost of Revenue growth rates for Entera Bio Ltd have been 33% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
